NCT05907954 2026-03-16(Neo)Adjuvant IDE196 (Darovasertib) in Patients With Localized Ocular MelanomaIDEAYA BiosciencesPhase 2 Active not recruiting160 enrolled
NCT01490632 2019-09-27A Phase 2b Study of Baricitinib in Participants With Moderate to Severe PsoriasisEli Lilly and CompanyPhase 2 Completed271 enrolled 32 charts
NCT01107457 2019-09-24A Study in Participants With Moderate to Severe PsoriasisEli Lilly and CompanyPhase 2 Completed142 enrolled 45 charts
NCT02908347 2019-01-23Study to Evaluate Safety and Efficacy of Oral MP1032 in Psoriasis PatientsMetrioPharm AGPhase 2 Completed46 enrolled 24 charts
NCT02201524 2016-10-05Study to Evaluate PF-04965842 in Patients With Moderate to Severe PsoriasisPfizerPhase 2 Terminated59 enrolled 18 charts